amyjoler

Momentum Life Sciences has been named a finalist in two categories of the 2026 PM360 Trailblazer Awards, recognizing innovative work and impact across the life sciences industry.

With more than 30 years of experience across nursing, specialty pharmacy, HUB operations, consulting, and patient services strategy, Tina Gafford joins Momentum Life Sciences as Director of Client Solutions.

Patient support programs have steadily expanded , adding more channels, more touchpoints, and more digital tools designed to keep patients informed and on therapy. But the experience patients describe often tells a different story. Despite the investments in personalization tools, channel optimization, and deep analytics around engagement, many patients report feeling less connected to their support program over time, not more.

Much of today's patient support is structured around the prescription — access, fulfillment, logistics. But some of the moments that most influence whether a patient initiates, adheres, and persists tend to happen somewhere else entirely: in the space between the prescription and the patient.

A quiet revolution is reshaping how therapies reach patients — and it’s happening faster than anyone expected. The pharmaceutical industry is experiencing a transformative shift towards Direct-to-Consumer (DTC) models, driven by several legislative and regulatory changes.

Artificial intelligence (AI) has advanced rapidly in its ability to understand language and detect emotion, giving pharmaceutical manufacturers powerful tools to scale and customize patient engagement. But AI on its own can’t deliver the kind of empathetic support patients truly need.

Discover the three essential pillars of rare disease support: medical expertise, community connections, and family engagement. Learn how integrating these elements creates comprehensive support networks for the 1 in 1,500 Americans affected by rare diseases.

Motivated patients are more likely to have better adherence and outcomes. Healthcare providers (HCPs) and families play crucial roles in treatment. Cancer mortality has significantly dropped over time, but nonadherence continues to be a problem. This is particularly so for patients taking oral oncolytics.

Measuring success in any endeavor requires a metric and scale by which to measure. Once this is determined, a method must be developed to determine how a company’s efforts rate.

The pharmaceutical industry continues to make a clear commitment to pharma patient engagement, and the total market investment is expected to increase more than 15% by 2030, according to Grand View Research.

Imagine losing your freedom daily. Dealing with the inability to leave your house in the morning. Missing out on birthdays, recitals, and family vacations... This is how 3.1 million adults in the US live every single day.

There are many opportunities for the biopharma industry to improve patients’ therapy journey and overall care.